Kelowna, British Columbia-based Okanagan Clinical Trials is currently conducting a study to determine the effectiveness of an investigational medication for Autism Spectrum Disorder in adults.
Dr. Paul Latimer, psychiatrist and principal investigator for Okanagan Clinical Trials reports “It is estimated one in every 66 Canadian children and youth aged five to 17 has autism spectrum disorder.” He continued, “Autism spectrum disorder (ASD) is a neurodevelopment disorder characterized by persistent deficits in social communication and social interaction and repetitive patterns of behaviors, interests or activities” he noted.
Presently finding help for autism is difficult. There are no pharmacological treatments available for the social and communication deficits in individuals with ASD, and as a consequence, there is a high unmet medical need for pharmacological therapies in the treatment of core symptoms in ASD. The Canadian research site is looking for volunteers who are men and women 19 years of age or older diagnosed with Autism Spectrum Disorder.
The study sponsor is looking for a total of 350 patients worldwide in the 24-week clinical study. In the British Columbia area, Okanagan Clinical Trials sees patients now.
Who are Okanagan Clinical Trials
A clinical research site in British Columbia, they conduct a diverse array of clinical trials based on their diversified group of investigators. Some of the therapeutic areas or illnesses they have studied and treated include:
- Generalized anxiety disorder
- Panic disorder
- Social anxiety disorder
- Bipolar disorder
- Attention deficit disorder
- Crohn’s disease
- Ulcerative colitis
- Celiac disease
- Neuropathic pain
- Opiate-induced constipation
- Alzheimer’s disease
They have been conducting clinical trials since 1992 and are well equipped to care out Phase II-IV trials in a variety of therapeutic areas. They have a team of medical specialists, research coordinators, and clerical staff that occupy 3,000 square feet with a modern medical building, ensuring excellent service for their patients and pharmaceutical sponsors.
Lead investigators include: